Internationally Renowned UCSD Physician-Researcher Chosen as Distinguished Scientist by American Heart Association


December 03, 2010  |  

Michael H.Criqui, MD, MPH, FAHA, professor and chief of the Division of Preventive Medicine in the Department of Family and Preventive Medicine at the University of California, San Diego was honored as a Distinguished Scientist by the American Heart Association (AHA) at this year’s AHA Scientific Sessions in Chicago, Illinois.  This is the highest honor given by the AHA.

Michael Criqui

Dr. Michael Criqui was named 1 of 5 AHA Distinguished Scientists for 2010

In 2003, the American Heart Association created a Distinguished Scientist designation to honor AHA/ASA members who have made extraordinary contributions to cardiovascular and stroke research.   This title recognizes seminal research work that has importantly advanced the understanding and management of cardiovascular disease or stroke.

Criqui is one of five honorees this year to join the ranks of 65 other preeminent researchers and scientists.  He is an active and productive investigator in cardiovascular epidemiology and preventive cardiology, and has made seminal contributions in the fields of peripheral arterial disease, subclinical atherosclerosis and peripheral venous disease.  Criqui has published over 385 manuscripts and book chapters and has been an invited lecturer at numerous national and international meetings.

# # #

Media Contact: Kim Edwards, 619-543-6163,

Related Specialties

Media Contact

Share This Article

Related News

New technique can reveal previously undetectable bacteria in places where they aren’t wanted — such as a spacecraft assembly facility, a neonatal intensive care unit and an abalone rearing center.
Each year, at precisely the same moment — 12 p.m. on the East coast, 9 a.m. on the West — thousands of graduating medical school students across the country simultaneously tear open an envelope. The s ...
Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate t ...
In clinical trial, treatment significantly reduced liver fat in NAFLD and NASH patients, offering possible new treatment for conditions that currently lack medical remedies.

Follow Us